Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The purpose of this research is to assess the feasibility (e.g., recruitment rate, adherence
rate and retention rate) of a clinical trial using virtual assessments to investigate the
effect of a 6-month administration of a specific multi-nutrient oral supplement on cognitive
aging.
The study will also test whether a 6-month daily intake of a specific multinutrient can delay
or reverse the effects of normal cognitive aging on other cognition domains as well as
quality of life as measured by virtual assessments.
Phase
Phase 2
Funding Agency/Sponsor
Other
Disease
Other
Enrollment Eligibility
Inclusion Criteria:
1. English or Spanish speaking participants considered to have age-related cognitive
decline based on the following criteria:
A) RBANS (Verbal Memory Retention) A score ≥70% on list learning retention AND ≥80% on
story memory retention and B) Subjective Cognitive Decline (SCD) 9-item brief
screening tool score within the 25th percentile (SCD =1) and 75th percentile (SCD = 6)
and C) MoCA ≥24
2. Age 55-89
3. Written informed consent provided by participant
Exclusion Criteria:
1. Enrollment in any other clinical trial within 30 days prior to participation
2. Major Neurocognitive Disorder ("Dementia") according to the Diagnostic and Statistical
Manual of Mental Disorders 5th Edition and/or NIAA Criteria
3. Use of any AD medication (e.g., cholinesterase inhibitors, NMDA antagonists), or OTC
supplements or cognitive/memory enhancers
4. Use of omega-3 fatty acids in the 30 days prior to participation
5. Intake of Vitamins B6 and B12, folate, Vitamins C and E > 300% RDI in the 24 days
prior to participation
6. Concurrent major medical or neurological illness
7. Prior clinical history of stroke
8. History of substance abuse (e.g., alcohol, drugs)
9. Untreated Major Depressive Disorder that has not been in remission for at least 6
months prior to participation